DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» MINE (chemotherapy)
MINE (chemotherapy)
©Ferrata Storti Foundation
Hodgkin Lymphoma Treatment Regimens
(Rituxan®), Rituximab-Abbs (Truxima®), Rituximab-Pvvr (Ruxience®) Prior Authorization Drug Coverage Policy
Effectiveness of Rituximab-Containing Treatment Regimens in Idiopathic Multicentric Castleman Disease
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’S Disease
High-Dose Mitoxantrone + Melphalan (MITO/L-PAM)
Ifosfamide and Etoposide-Based Chemotherapy As Salvage and Mobilizing Regimens for Poor Prognosis Lymphoma
Acronyms for Oncology Regimens
United States Patent (19) 11 Patent Number: 6,048,849 Hausheer Et Al
Managing Relapsed and Refractory DLBCL
High-Grade Non-Hodgkin Lymphoma
Proposal for the Inclusion of Mesna (Sodium 2-Mercaptoethane Sulfonate)
DNA Topoisomerases of Kinetoplastid Parasites: Brief Overview and Recent Perspectives
Diffuse Large B-Cell Lymphoma, Second-Line Therapy
Ifosfamide.Pdf
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
Mitoxantrone (Novantrone) Reference Number: ERX.SPA.118 Effective Date: 10.01.16 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Cost-Effectiveness Analysis of Rituximab Maintenance Treatment
Top View
NIOSH Alert: Preventing Occupational Exposures to Antineoplastic
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), First- Line Therapy
Pharmacy Policy Statement
Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma
Mitoxantrone (Novantrone)
Mitoxantrone Class:Anthracenedione Indications
Ifosfamide Inclusion.Pdf